Skip to main content

Advertisement

SpringerLink
Log in

IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223–3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60:615–21.

    Article  PubMed  Google Scholar 

  2. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, et al. Basic research in kidney cancer. Eur Urol. 2011;60:622–33.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193–205.

    Article  PubMed  Google Scholar 

  4. Lang H, Lindner W, de Fromont M, Molinie V, Letourneux H, Meyer N, et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma—assessment of 241 patients with >15-year follow-up. Cancer. 2005;103:625–9.

    Article  PubMed  Google Scholar 

  5. Zisman A. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559–66.

    Article  PubMed  Google Scholar 

  6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395–400.

    Article  PubMed  Google Scholar 

  7. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011;60:644–61.

    Article  PubMed  Google Scholar 

  8. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN, Lukic ML. IL-33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunol. 2012;1:229–31.

    Article  CAS  Google Scholar 

  9. Zhao Q, Chen G. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. BioMed Res Int. 2014;2014:587376.

    PubMed  PubMed Central  Google Scholar 

  10. Jiang HR, Milovanovic M, Allan D, Niedbala W, Besnard AG, Fukada SY, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol. 2012;42:1804–14.

    Article  CAS  PubMed  Google Scholar 

  11. Schmitz J, Owyang A, Oldham E, Song YL, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.

    Article  CAS  PubMed  Google Scholar 

  12. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22.

    Article  CAS  Google Scholar 

  13. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008;3, e3331.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood. 2009;114:3117–26.

    Article  CAS  PubMed  Google Scholar 

  15. Joshi AD, Oak SR, Hartigan AJ, Finn WG, Kunkel SL, Duffy KE, et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 2010;11:52.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Masamune A, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol-Gastr L. 2010;299:G821–32.

    CAS  Google Scholar 

  17. Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, et al. High serum levels of the interleukin 33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. J Hepatol. 2013;58:S257–7.

    Article  Google Scholar 

  18. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer J Int Du Cancer. 2014;134:1669–82.

    Article  CAS  Google Scholar 

  19. Hu L-A, Fu Y, Zhang D-N, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14:2563–6.

    Article  PubMed  Google Scholar 

  20. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.

    Article  PubMed  Google Scholar 

  21. Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, et al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1129–36.

    Article  Google Scholar 

  22. Mager LF, Riether C, Schurch CM, Banz Y, Wasmer MH, Stuber R, et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015;125:2579–91.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, Hu WH. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci. 2015;60:1265–72.

    Article  CAS  PubMed  Google Scholar 

  24. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.

    Article  CAS  PubMed  Google Scholar 

  26. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol. 2011;41:1902–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study was funded by grants from the National Basic Research Program of China (2012CB822104), National Key Projects for Infectious Diseases of China (2012ZX10002012-007, 2016ZX10002018-008), National Natural Science Foundation of China (31100629, 31270863, 81372755, 31470794, 81401988, 81402082, 81402085, 81471621, 81472227, 81472376, 31570803, 81501999, and 81572352), and Program for New Century Excellent Talents in University (NCET-13-0146). All these study sponsors have no roles in the study design, in the collection, analysis, and interpretation of data.

Author information

Author notes

    Authors and Affiliations

    1. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China

      Zewei Wang, Hangcheng Fu & Jiejie Xu

    2. Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

      Le Xu

    3. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

      Yuan Chang, Lin Zhou & Yuanfeng Yang

    4. Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China

      Weijuan Zhang

    Authors
    1. Zewei Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Le Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yuan Chang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Lin Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Hangcheng Fu
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Weijuan Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Yuanfeng Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Jiejie Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Yuanfeng Yang or Jiejie Xu.

    Ethics declarations

    Conflicts of interest

    None

    Additional information

    Zewei Wang, Le Xu and Yuan Chang contributed equally to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Figure S1

    Kaplan-Meier analysis of OS in patients with TNM stage III (a) and stage IV (b) based on the expression of IL-33. Kaplan-Meier analysis of RFS in patients with T3-4N0M0 (c). P value was calculated by log-rank test. (GIF 16 kb)

    High Resolution Image (TIF 466 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wang, Z., Xu, L., Chang, Y. et al. IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma. Tumor Biol. 37, 11127–11134 (2016). https://doi.org/10.1007/s13277-016-4879-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-016-4879-3

    Keywords

    Search

    Navigation